Research programme: amyotrophic lateral sclerosis therapies - CepTor

Drug Profile

Research programme: amyotrophic lateral sclerosis therapies - CepTor

Alternative Names: C-202

Latest Information Update: 09 Jul 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CepTor Corporation
  • Class Alkanesulfonic-acids; Amino acids; Antiepileptic drugs; Pentanoic acids
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 01 Mar 2005 Ceptor Corporation is now an independent company
  • 26 Feb 2004 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top